Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
J Thorac Oncol. 2010 Nov;5(11):1764-71. doi: 10.1097/JTO.0b013e3181f69f08.
Primary lung adenocarcinoma is extremely rare in the pediatric age group. There have been anecdotal reports of lesions that are histologically indistinguishable from adult-type pulmonary adenocarcinoma in young patients after treatment for nonpulmonary cancers. Herein, we present clinical, histopathologic, and molecular data on eight such cases.
Histopathologic evaluation of the tumors was performed according to the World Health Organization classification. Molecular studies for EGFR and KRAS mutations were performed on six patients with sufficient material.
All eight patients were never smokers, four males and four females. Median age at nonpulmonary cancer diagnosis was 14 years (range, 3-23 years). Pulmonary adenocarcinomas were diagnosed at a median age of 15 years (range, 10-24 years); tumors were 0.1 to 2.0 cm in size and in some cases coexisted with metastases from the original cancer. Retrospective review showed that in at least three patients, the nodules were radiographically present before chemotherapy. Of six patients whose tumors were tested for common EGFR and KRAS mutations, two were positive for the former and one for the latter. At a median follow-up of 11 months (range, 2-29 months), six patients remained well without lung nodules and two had additional small, peripheral lung nodules that have not been biopsied.
Pulmonary lesions found in young patients with pediatric cancers can be histologically indistinguishable from lung adenocarcinoma seen in adults, may display typical adenocarcinoma-associated mutations of EGFR and KRAS, and may precede the administration of cytotoxic chemotherapy.
原发性肺腺癌在儿科年龄组中极为罕见。有一些偶发报道称,在治疗非肺部癌症后,年轻患者的病变在组织学上与成人型肺腺癌无法区分。在此,我们报告了 8 例此类病例的临床、组织病理学和分子数据。
根据世界卫生组织分类对肿瘤进行组织病理学评估。对 6 例有足够材料的患者进行 EGFR 和 KRAS 突变的分子研究。
8 例患者均为从不吸烟者,男女各 4 例。非肺部癌症诊断时的中位年龄为 14 岁(范围 3-23 岁)。肺腺癌的诊断中位年龄为 15 岁(范围 10-24 岁);肿瘤大小为 0.1 至 2.0cm,在某些情况下与原始癌症的转移共存。回顾性研究表明,至少有 3 例患者在化疗前,肺部结节在影像学上已经存在。在对 6 例肿瘤进行常见 EGFR 和 KRAS 突变检测的患者中,有 2 例前者阳性,1 例后者阳性。在中位随访 11 个月(范围 2-29 个月)时,6 例患者病情良好,无肺部结节,2 例患者有另外的小的、外周性肺部结节,但尚未进行活检。
在患有儿科癌症的年轻患者中发现的肺部病变在组织学上可能与成人型肺腺癌无法区分,可能表现出典型的腺癌相关的 EGFR 和 KRAS 突变,并且可能在细胞毒性化疗之前出现。